System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Andrea Dalbeni is an expert in Hepatology at Azienda Ospedaliera Universitaria Integrata Verona (Italy). Andrea Dalbeni has authored 225 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 1 of them ongoing. SLR score: 696 (community average: 125). How the SLR is computed.

LeadR Profile

Andrea Dalbeni Azienda Ospedaliera Universitaria Integrata Verona Italy
696 ScienceLeadR Reputation 696

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Oncology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2012 - 2026
Source: PubMed

University of Verona

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 225

Citations

Citations: 2 828 1st author: 55 Last author: 28 Unique author: 0

Main journals

Dig Liver Dis 51
J Hepatol 29
Ann Rheum Dis 7
Intern Emerg Med 7
Int J Mol Sci 6

Best Journals

J Hepatol 13
Ann Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores.
PMID 42839680 — bevacizumab, liver, therapeutics		Liver Int20260
Author's reply: ``Survival fragility in advanced hepatocellular carcinoma immunotherapy trials requires clinical context''.
PMID 42570884 — carcinoma, hepatocellular, immunotherapy		Dig Liver Dis20260
Orthostatic Hypotension in Hypertensive Patients Hospitalized in Italian Internal Medicine Departments: FADOI-HYP-OP Study.
PMID 42455464 — adrenergic agents, comorbidity, blood, internal medicine, blood pressure, receptors, adrenergic, hypotension, orthostatic, prevalence, hypotension		High Blood Press Cardiovasc Prev20260
Interleukin-8 in health and disease.
PMID 42423773 — cells, pathology, interleukin-8, liver, biomarkers, sepsis, diagnosis		Mol Biomed20261
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.
PMID 42297215 — liver diseases, cells, phenotype, multiple chronic conditions, bevacizumab, liver, immunotherapy, therapeutics, tissues		J Hepatol Top journal20263

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 3
Phase 2 1

By status:

Active not recruiting 1
Completed 1
Recruiting 1
Unknown 1

By type:

Observational 3
Interventional 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Atezolizumab bevacizumab and Other Immunotherapies Real life Experience for Treatment of Hepatocellular Carcinoma
NCT06806579 — carcinoma, hepatocellular, neoplasms, bevacizumab, liver, immunotherapy, liver neoplasms, therapeutics, carcinoma		N/ARecruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS